Seelos Therapeutics, Inc. Market Cap ($58.00)
Market Cap & Net Worth: Seelos Therapeutics, Inc. (SEELQ)
Seelos Therapeutics, Inc. market cap. Seelos Therapeutics, Inc. (NASDAQ:SEELQ) has a market capitalization of $58.00 ($58.00) as of November 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32078 globally and #6486 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seelos Therapeutics, Inc.'s stock price $0.00 by its total outstanding shares 581000 (581.00K). Also see Seelos Therapeutics, Inc. (SEELQ) cash flow conversion for how efficiently the company converts equity into cash flow.
Seelos Therapeutics, Inc. Market Cap History (2026–2026)
Seelos Therapeutics, Inc. market cap history from 2026 to 2026. Data shows growth from $58.10 to $58.10 (0.00% CAGR). Check current stock price of Seelos Therapeutics, Inc. for real-time trading data and today's change.
Seelos Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seelos Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Seelos Therapeutics, Inc. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SEELQ by Market Capitalization
Companies near Seelos Therapeutics, Inc. in the global market cap rankings as of November 3, 2026. Also see Seelos Therapeutics, Inc. total assets for a full breakdown of the balance sheet.
Key companies related to Seelos Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Seelos Therapeutics, Inc. (2026–2026)
Market capitalization of Seelos Therapeutics, Inc. from 2026 to today. Between 2026 and today, Seelos Therapeutics, Inc.'s market cap moved from $58.10 to $ 58.10, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $58.10 | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Seelos Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $58.00 USD |
| MoneyControl | $58.00 USD |
| MarketWatch | $58.00 USD |
| marketcap.company | $58.00 USD |
| Reuters | $58.00 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therap… Read more